Trials / Completed
CompletedNCT01267279
Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Spokane Joint Replacement Center · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
In a randomized, double-blind trial, BMD of the operated proximal femur after total hip replacement measured by dual-energy x-ray absorptiometry (DXA) were compared for up to two years in patients receiving IV ZOL 5 mg infusion (n = 27) or placebo (IV saline infusion; n = 24) at two weeks and one year after surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zoledronic acid | Zoledronic acid per protocol |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2010-12-28
- Last updated
- 2018-12-19
- Results posted
- 2018-12-19
Source: ClinicalTrials.gov record NCT01267279. Inclusion in this directory is not an endorsement.